{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:51:33Z","timestamp":1789105893321,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its prognostic value in CA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A self-reported questionnaire, \u201cAmylo-AFFECT\u201d had been designed and validated for CA symptoms evaluation and screening by physicians. It was adapted here to assess HR-QoL (Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the theoretical model, internal consistency and convergent validity were assessed, particularly correlations between Amylo-AFFECT-QOL and the HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Amylo-AFFECT-QOL was completed by 515 patients, 425 of whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis (ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL evaluation was obtained with five dimensions: \u201cHeart failure,\u201d \u201cVascular dysautonomia,\u201d \u201cNeuropathy,\u201d \u201cEar, gastrointestinal, and urinary dysautonomia,\u201d and \u201cSkin or mucosal involvement.\u201d The global Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations (rs = 0.72, <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Patients with a final diagnosis of CA had a global Amylo-AFFECT-QOL score significantly higher than the control group composed by patients with other diagnoses (22.2 \u00b1 13.6 vs. 16.2 \u00b1 13.8, respectively, <jats:italic>p<\/jats:italic>-value &amp;lt; 0.01). According to the Amylo-AFFECT-QOL global results, ATTRv patients\u2019 QoL was more affected than AL patients\u2019 QoL or ATTRwt patients\u2019 QoL. Patients with a higher HR-QoL score had a greater risk of death or heart transplant after 1 year of follow-up (log-rank &amp;lt; 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Amylo-AFFECT-QOL demonstrates good psychometric properties and is useful for quantifying HR-QoL and estimating CA prognosis. Its use may help to improve overall management of patients with CA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1124660","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T04:35:51Z","timestamp":1678768551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Mounira","family":"Kharoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"B\u00e9zard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Broussier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnault","family":"Galat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Gounot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Poullot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Molinier-Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Fanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Funalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan Deep","family":"Sing Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soulef","family":"Guendouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Zaroui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Audureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Hittinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Plant\u00e9 Bordeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Lefaucheur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bequignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Teiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Oghina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000289","article-title":"Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy.","volume":"3","author":"Damy","year":"2016","journal-title":"Open Heart."},{"key":"B2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS).","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management.","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies.","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1002\/ehf2.13652","article-title":"History of extracardiac\/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.","volume":"8","author":"Kharoubi","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial).","volume":"141","author":"Hanna","year":"2021","journal-title":"Am J Cardiol."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omab059","article-title":"Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR).","volume":"2021","author":"Rahman","year":"2021","journal-title":"Oxf Med Case Rep."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/0002-9149(93)90582-W","article-title":"Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo.","volume":"71","author":"Rector","year":"1993","journal-title":"Am J Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ehf2.12363","article-title":"Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach: HR-QoL assessment in HF outpatients.","volume":"6","author":"Gallagher","year":"2019","journal-title":"ESC Heart Fail."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy.","volume":"19","author":"Vinik","year":"2014","journal-title":"J Peripher Nerv Syst."},{"key":"B13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mus.25257","article-title":"Clinical measures in transthyretin familial amyloid polyneuropathy.","volume":"55","author":"Coelho","year":"2017","journal-title":"Muscle Nerve."},{"key":"B14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.26515","article-title":"Burden of hereditary transthyretin amyloidosis on quality of life.","volume":"60","author":"Yarlas","year":"2019","journal-title":"Muscle Nerve."},{"key":"B15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ajh.24676","article-title":"Hematology patient reported symptom screen to assess quality of life for AL amyloidosis.","volume":"92","author":"Warsame","year":"2017","journal-title":"Am J Hematol."},{"key":"B16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis.","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jnu.12318","article-title":"Cross-validation of the minnesota living with heart failure questionnaire.","volume":"49","author":"Mogle","year":"2017","journal-title":"J Nurs Scholarsh."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","article-title":"Assessment of patient outcome with the minnesota living with heart failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan.","volume":"124","author":"Rector","year":"1992","journal-title":"Am Heart J."},{"key":"B19","first-page":"258 p","author":"Rubin","year":"2004","journal-title":"Multiple imputation for nonresponse in surveys."},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13598","article-title":"Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest."},{"key":"B21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid."},{"key":"B22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/heart.87.3.235","article-title":"Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables.","volume":"87","author":"Juenger","year":"2002","journal-title":"Heart."},{"key":"B23","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure.","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41409-020-0990-6","article-title":"Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation.","volume":"56","author":"Al Saleh","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1124660\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T04:36:09Z","timestamp":1678768569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1124660\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2023.1124660"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1124660","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"1124660"}}